Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COH29 in Advanced Solid Tumors
NCT02112565Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COH29 in solid tumor, sponsored by City of Hope. Primary endpoint: Maximum Tolerated Dose at Day 28. Started Jan 2017; status: active, not recruiting.
02
Drugs
COH29
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02112565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112565.